DrugPatentWatch Database Preview
Details for Patent: 8,791,154
Which drugs does patent 8,791,154 protect, and when does it expire?
This patent has twenty-seven patent family members in seventeen countries.
Summary for Patent: 8,791,154
Title: | High concentration olopatadine ophthalmic composition |
Abstract: | The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis. |
Inventor(s): | Gamache; Daniel A. (Arlington, TX), Alani; Laman (Fort Worth, TX), Ghosh; Malay (Fort Worth, TX), Galan; Francisco Javier (Barcelona, ES), Perdiguer; N ria Carreras (Barcelona, ES), Singh; Onkar N. (Arlington, TX) |
Assignee: | Alcon Research, Ltd. (Fort Worth, TX) |
Application Number: | 13/475,607 |
Patent Claim Types: see list of patent claims | Use; Formulation; Compound; |
Drugs Protected by US Patent 8,791,154
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharms Corp | PAZEO | olopatadine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 206276-001 | Jan 30, 2015 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS | ➤ Try a Free Trial | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,791,154
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,533,053 | High concentration olopatadine ophthalmic composition | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 8,791,154
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 086490 | ➤ Try a Free Trial | |||
Australia | 2012255046 | ➤ Try a Free Trial | |||
Canada | 2826725 | ➤ Try a Free Trial | |||
China | 103458894 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |